Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06776419Recruiting

the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease

Role: lead

NCT06325488Recruiting

Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease

Role: lead

NCT06303466Active Not Recruiting

Real World Evidence Study of Danish Fabry Patients

Role: lead

NCT05599438Recruiting

Prospective, Longitudinal Study on FItness DOping in DenmarK

Role: lead

All 4 trials loaded